News

Takeda Pharmaceutical Company Limited and COUR Pharmaceutical Development Company, Inc. announced that Takeda has acquired an exclusive global license to develop and commercialize the…
Read More...

Biogen and Eisai, Co., Ltd. announced that, after consulting with the U.S. Food and Drug Administration (FDA), Biogen plans to pursue regulatory approval for aducanumab, an…
Read More...

Bryn Pharma announced that it has entered into an agreement with Aptar Pharma, a leading drug delivery systems provider, for the supply and worldwide exclusive right to use Aptar's…
Read More...

Moberg Pharma AB has signed a distribution agreement with DongKoo Bio & Pharma Co., Ltd for MOB-015 in the Republic of Korea. Under the agreement DongKoo is granted exclusive rights…
Read More...

Odonate Therapeutics, a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced the…
Read More...

Knight Therapeutics Inc. announced that it has entered into a definitive agreement under which Knight will acquire a 51.21% interest in Biotoscana Investments S.A. (B3: GBIO33) from a…
Read More...

GlaxoSmithKline plc announced the divestment of travel vaccines Rabipur (tradename Rabavert in the US) for the prevention of rabies, and Encepur for the prevention of tick-borne…
Read More...

AstraZeneca announced that the US Food and Drug Administration (FDA) has approved Farxiga (dapagliflozin) to reduce the risk of hospitalisation for heart failure (hHF) in adults with…
Read More...

Verseau Therapeutics, Inc. launched with $50 million in financing from 20/20 HealthCare Partners, 3SBio, Alexandria Venture Investments, Highlight Capital, InHarv Partners Ltd., The…
Read More...

The Janssen Pharmaceutical Companies of Johnson & Johnson announced the U.S. Food and Drug Administration's (FDA) approval of STELARA® (ustekinumab) for the treatment of adult…
Read More...

Biogen Inc. and Samsung Bioepis announced that they will present new real-world data from the companies’ anti-TNF biosimilar portfolio, which includes FLIXABI (infliximab) and IMRALDI…
Read More...

Alexion Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) approved ULTOMIRIS (ravulizumab-cwvz) for the treatment of atypical hemolytic uremic syndrome (aHUS)…
Read More...

Merck, known as MSD outside the United States and Canada, announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a…
Read More...

Thermo Fisher Scientific, the world leader in serving science, announced the availability of the Thermo Scientific Acrometrix BCR-ABL Panel, its latest molecular quality control panel.…
Read More...

Horizon Therapeutics plc announced it has initiated an open-label clinical trial evaluating the use of KRYSTEXXA (pegloticase injection) in adults with chronic gout refractory to…
Read More...

AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo) announced that the US Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA)…
Read More...

ArsenalBio makes its debut today backed by $85 million Series A financing to build a programmable cell therapy company to create highly effective and accessible immune cell therapies.…
Read More...

Teijin Limited (Teijin) and NeuroSigma, Inc. (NeuroSigma), a Los Angeles-based bioelectronics company focused on developing Trigeminal Nerve Stimulation (TNS) technology for the…
Read More...

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, announced the submission of a supplemental New Drug…
Read More...

Mesoblast and Lonza announced that they have entered into an agreement for commercial manufacture of Mesoblast’s lead allogeneic (off-the-shelf) cell therapy product candidate,…
Read More...